CN115397463A - 抗非洲猪瘟病毒感染的疫苗 - Google Patents

抗非洲猪瘟病毒感染的疫苗 Download PDF

Info

Publication number
CN115397463A
CN115397463A CN202180019234.9A CN202180019234A CN115397463A CN 115397463 A CN115397463 A CN 115397463A CN 202180019234 A CN202180019234 A CN 202180019234A CN 115397463 A CN115397463 A CN 115397463A
Authority
CN
China
Prior art keywords
mgf
gene
seq
attenuated
asfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180019234.9A
Other languages
English (en)
Chinese (zh)
Inventor
L.迪克森
A.里斯
S.康奈尔
A.拉塔克里什南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pirbright Institute
Original Assignee
Pirbright Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by Pirbright Institute filed Critical Pirbright Institute
Publication of CN115397463A publication Critical patent/CN115397463A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12061Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12061Methods of inactivation or attenuation
    • C12N2710/12062Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180019234.9A 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗 Pending CN115397463A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2003292.6 2020-03-06
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GB2003289.2 2020-03-06
GB2005880.6 2020-04-22
GB2005878.0 2020-04-22
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2013541.4 2020-08-28
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050561 WO2021176235A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
CN115397463A true CN115397463A (zh) 2022-11-25

Family

ID=74870840

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180019234.9A Pending CN115397463A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗
CN202180019437.8A Pending CN115605223A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗
CN202180019982.7A Pending CN116133680A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202180019437.8A Pending CN115605223A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗
CN202180019982.7A Pending CN116133680A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗

Country Status (13)

Country Link
US (3) US20240293525A1 (https=)
EP (3) EP4114454A1 (https=)
JP (2) JP2023516713A (https=)
KR (2) KR20230013016A (https=)
CN (3) CN115397463A (https=)
AU (2) AU2021229654A1 (https=)
BR (2) BR112022016893A8 (https=)
CA (2) CA3170043A1 (https=)
CL (2) CL2022002412A1 (https=)
CO (2) CO2022014152A2 (https=)
MX (2) MX2022010373A (https=)
PH (2) PH12022552084A1 (https=)
WO (3) WO2021176235A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN120282794A (zh) * 2022-08-04 2025-07-08 T·马尔科姆 针对非洲猪瘟病毒的猪的预防和感染后治疗的显性负性抗原方法
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459931A (zh) * 2014-06-19 2017-02-22 皮尔布莱特研究所 减毒的非洲猪瘟病毒疫苗
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459931A (zh) * 2014-06-19 2017-02-22 皮尔布莱特研究所 减毒的非洲猪瘟病毒疫苗
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEXANDRA HÜBNER等: "Identification and characterization of the 285L and K145R proteins of African swine fever virus", J GEN VIROL., vol. 100, no. 9, 30 July 2017 (2017-07-30), pages 1307 *
VIVIAN O\'DONNELL等: "African Swine Fever Virus Georgia Isolate Harboring Deletions of MGF360 and MGF505 Genes Is Attenuated in Swine and Confers Protection against Challenge with Virulent Parental Virus", J VIROL., vol. 89, no. 11, 25 March 2015 (2015-03-25) *

Also Published As

Publication number Publication date
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
BR112022016893A2 (pt) 2023-01-24
CA3170058A1 (en) 2021-09-10
CN116133680A (zh) 2023-05-16
BR112022016893A8 (pt) 2023-02-28
US20240293525A1 (en) 2024-09-05
EP4114453A1 (en) 2023-01-11
WO2021176235A1 (en) 2021-09-10
CO2022014256A2 (es) 2022-12-30
EP4114454A1 (en) 2023-01-11
EP4114455A1 (en) 2023-01-11
WO2021176236A1 (en) 2021-09-10
US20230124042A1 (en) 2023-04-20
MX2022010372A (es) 2023-01-19
KR20230013017A (ko) 2023-01-26
JP2023516713A (ja) 2023-04-20
AU2021229654A1 (en) 2022-11-03
CN115605223A (zh) 2023-01-13
KR20230013016A (ko) 2023-01-26
CA3170043A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
PH12022552084A1 (en) 2024-02-26
CL2022002412A1 (es) 2023-03-03
JP2023516709A (ja) 2023-04-20
CL2022002416A1 (es) 2023-03-03
MX2022010373A (es) 2023-01-19
PH12022552086A1 (en) 2023-11-20
CO2022014152A2 (es) 2023-02-16
AU2021231402A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CN115397463A (zh) 抗非洲猪瘟病毒感染的疫苗
JP7121950B2 (ja) 合理的に開発されたアフリカ豚コレラ弱毒化ウイルス株による、ジョージア2007単離株親ウイルスの攻撃に対する防護
JP7591043B2 (ja) 遺伝子i177lの欠失に基づく新規なアフリカ豚熱弱毒化生ワクチンの開発
CN113215109B (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
JPS60231620A (ja) 変性された生きている偽狂犬病ウイルス、それを含有する偽狂犬病ワクチン、それを生産する方法およびそれを使用する方法
CN112899290B (zh) 一种天然免疫抑制基因缺失的减毒非洲猪瘟病毒株及应用
CN114107228B (zh) 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
CN113151310B (zh) 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用
CN113025629A (zh) 一种基因缺失的减毒非洲猪瘟病毒株及应用
CN114015660B (zh) 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
WO2016049101A1 (en) Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate
CN111925994B (zh) 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用
JPH04504357A (ja) ワクシニアベクター、ワクシニア遺伝子およびその発現産物
JP2024500225A (ja) 安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失
JP7387623B2 (ja) 標的タンパク質を安定して発現できる組換えウイルス
WO2006002594A1 (en) A recombinant canine adenovirus type-2 and the preparation method and usage thereof
TW202523348A (zh) Dev作載體的禽流感h9疫苗
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
CN111712575B (zh) 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
Pérez-Núñez et al. Generation and Genetic Stability of a PolX and 5′ MGF-Deficient African Swine Fever Virus Mutant for Vaccine Development. Vaccines 2024, 12, 1125
KR20250179193A (ko) 아프리카 돼지 열병 바이러스 백신용 다중 에피토프 및 이의 용도
WO2025049941A1 (en) Attenuated vaccinia virus vaccines for monkeypox

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination